BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1376 related articles for article (PubMed ID: 23954175)

  • 1. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
    Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
    J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Zhang S; Smailagic N; Hyde C; Noel-Storr AH; Takwoingi Y; McShane R; Feng J
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010386. PubMed ID: 25052054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression.
    Teipel SJ; Kurth J; Krause B; Grothe MJ;
    Neuroimage Clin; 2015; 8():583-93. PubMed ID: 26199870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
    Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
    Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
    Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
    Shea YF; Ha J; Lee SC; Chu LW
    Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.